Cargando…
Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were include...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094525/ https://www.ncbi.nlm.nih.gov/pubmed/35544533 http://dx.doi.org/10.1371/journal.pone.0268353 |
_version_ | 1784705557080309760 |
---|---|
author | Kang, Hae Min Hasanuzzaman, Md. Kim, So Won Koh, Hyoung Jun Lee, Sung Chul |
author_facet | Kang, Hae Min Hasanuzzaman, Md. Kim, So Won Koh, Hyoung Jun Lee, Sung Chul |
author_sort | Kang, Hae Min |
collection | PubMed |
description | PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group. RESULTS: Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0–21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6–2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7–3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0–20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0–21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3–4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0–7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively). CONCLUSION: The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR. |
format | Online Article Text |
id | pubmed-9094525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90945252022-05-12 Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy Kang, Hae Min Hasanuzzaman, Md. Kim, So Won Koh, Hyoung Jun Lee, Sung Chul PLoS One Research Article PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group. RESULTS: Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0–21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6–2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7–3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0–20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0–21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3–4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0–7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively). CONCLUSION: The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR. Public Library of Science 2022-05-11 /pmc/articles/PMC9094525/ /pubmed/35544533 http://dx.doi.org/10.1371/journal.pone.0268353 Text en © 2022 Kang et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kang, Hae Min Hasanuzzaman, Md. Kim, So Won Koh, Hyoung Jun Lee, Sung Chul Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title | Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title_full | Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title_fullStr | Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title_full_unstemmed | Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title_short | Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
title_sort | elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094525/ https://www.ncbi.nlm.nih.gov/pubmed/35544533 http://dx.doi.org/10.1371/journal.pone.0268353 |
work_keys_str_mv | AT kanghaemin elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy AT hasanuzzamanmd elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy AT kimsowon elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy AT kohhyoungjun elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy AT leesungchul elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy |